Stifel Nicolaus initiated coverage on Johnson & Johnson JNJ with a Hold rating.
Stifel Nicolaus noted, "We are initiating coverage of Johnson & Johnson (JNJ) with a Hold rating. We see JNJ as a core health care holding and total return vehicle in any environment for investors looking for safety and stability, particularly in these uncertain times. As JNJ continues to resolve recent issues and ex-FX sales growth reaccelerates modestly in each year over the next few years, JNJ shares should sustain its 12.6x forward P/E multiple, in line with the S&P 500."
Johnson & Johnson closed at $69.19 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in